May 18, 2022
2 min watch
Save
VIDEO: New scale enables patients to rate effects of diabetic retinopathy therapy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
DENVER — Researchers developed a patient-reported outcome instrument to assess the effects of anti-VEGF agents or panretinal photocoagulation for diabetic retinopathy, according to a study presented here at the ARVO meeting.
Diana Do, MD, of Byers Eye Institute, Stanford University, said patients can use the Diabetic Retinopathy Scale to provide feedback on visual symptoms, emotional impact and health-related quality of life changes.
Published by:
Sources/Disclosures
Collapse
Source:
Do D, et al. Development of a new patient-reported outcome instrument to assess diabetic retinopathy treatment experiences. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.
Disclosures:
Do reports receiving research funding from and consulting for Regeneron.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.